Interview with Edwin Harvey, Managing Director, Biogen Idec Argentina
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
Address: Av. del Libertador 350 – 7th Floor
1638 Vicente Lopez – Buenos Aires
Argentina
Tel: +54 11 5550 8150
Web: http://www.biogenidec.com/
Biogen Idec Argentina is part of a multinational company, headquartered in Cambridge, Massachusetts which has, since its formation, gained a commercial presence in over 29 markets. Their two leading products, AVONEX and RITUXAN, have for years ranked among the top ten biotechnology products sold globally.
Biogen Idec’s presence in Argentina provides therapeutic solutions through knowledge, research and support programs for the local multiple sclerosis. A great deal of commitment is shown to this new market as investment is flowing in the form of an R&D laboratory. This new venture in Latin America, and offices in Brazil and now Argentina, allows Biogen Idec to reach patients throughout the whole region.
Neurology
Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in…
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
See our Cookie Privacy Policy Here
